The efficacy of prostate-specific antigen screening: Impact of key components in the ERSPC and PLCO trials.
Harry J de KoningRoman GulatiSue M MossJonas HugossonPaul F PinskyChristine D BergAnssi AuvinenGerald L AndrioleMonique J RoobolE David CrawfordVera NelenMaciej KwiatkowskiMarco ZappaMarcos LujánArnauld VillersTiago M de CarvalhoEric J FeuerAlex TsodikovAngela B MariottoEveline A M HeijnsdijkRuth EtzioniPublished in: Cancer (2017)
The observed cancer mortality reduction in screening trials appears to be highly sensitive to trial protocol and practice settings. Accounting for these differences, the efficacy of PSA screening in the PLCO setting is not necessarily inconsistent with ERSPC results. Cancer 2018;124:1197-206. © 2017 American Cancer Society.